


3.2.1 Extramural funding for Research (Grants sponsored by the non-government sources such as industry, corporate houses, international bodies for research projects) endowments, Chairs in the University during the year(INR in Lakhs)

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project
Three field radical esophagectomy versus two field esophagectomy a prospective randomized controlled trial	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2004	1.98	19 Years
A prospective randomized trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IIIB squamous carcinoma of the uterine cervix	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2003	3.32	19 Years 5 Months 20 Days
Phase III trial of surgery followed by conventional radiotherapy (5 fractions/ week) vs concurrent chemoradiotherapy vs accelerated radiotherapy (6 Fractions/week) in high risk, locally advanced stage III & IVA, resectable, squamous cell carcinoma of oral cavity	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2005	2.17	18 Years 5 Months 15 Days
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial)	Dr. Vani Parmar	ETOP - INTERNATIONAL BREAST CANCER STUDY GROUP	Non-Government	Medical & Health Sciences	2005	2.23	18 Years
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial)	Dr. Vani Parmar	ETOP - INTERNATIONAL BREAST CANCER STUDY GROUP	Non-Government	Medical & Health Sciences	2005	1.51	18 Years
Inter laboratory comparison program for immunophenotyping by flow cytometry	Dr. Sumeet Gujral	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2006	0.60	25 Years 5 Months 18 Days
Prospective, collaborative, multi-center multi-national, open cohort study evaluating device associated nosocomial infection rates, extra days, extra costs, antibiotic use, bacterial resistance, mortality, risk factors, infection control process surveillance and cost effectiveness in coronary, medical surgical, mixed, adults, pediatric and newborns intensive care units in Health care settings	Dr. Sheila Myatra	International Nosocomial Infection Control Consortium (INICC)	Non-Government	Medical & Health Sciences	2007	0.06	21 Years 9 Months 22 Days
ALTO-EGF106708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib,Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer	Dr. Sudeep Gupta	NOVARTIS	Non-Government	Medical & Health Sciences	2008	4.21	15 Years
Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline.	Dr. Rajesh Dikshit	World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC)	Non-Government	Medical & Health Sciences	2008	9.23	


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमि भाभा राष्ट्रीय संस्थान
 9.23.13

Compilation of data as received from
 Dean-Academics of various CI's/Occ of HBNI

Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial	Dr. Sharmila Pimple	International Agency for Research on Cancer, World Health Organization, Lyon, France	Non-Government	Medical & Health Sciences	2008	9.85	18 Years
A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2010	1.29	12 Years
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)	Dr. Kumar Prabhash	BIOCON	Non-Government	Medical & Health Sciences	2011	6.32	13 Years
Asia CML Registry (ACR): Web based registry	Dr. Navin Khattry	ASIAN GOVERNMENT RESERACH FUND	Non-Government	Medical & Health Sciences	2011	.21	13 Years
Protocol No. - D420000000 : Study Code D4200C00088-A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib	Dr. Vanita Noronha	SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL)	Non-Government	Medical & Health Sciences	2011	1.18	13 Years
Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer	Dr. Kumar Prabhash	ICON	Non-Government	Medical & Health Sciences	2012	2.61	10 Years
Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India.	Dr. Vanita Noronha	ICON	Non-Government	Medical & Health Sciences	2012	.33	11 Years
A Randomized controlled study to evaluate the role of hydroxy-progesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2013	7.29	11 Years
Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry)	Dr. Shailesh Shrikhande	Merck PVT Ltd.	Non-Government	Medical & Health Sciences	2013	.99	9 Years
Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India	Dr. Kumar Prabhash	SANOFI	Non-Government	Medical & Health Sciences	2015	7.97	9 Years
A collaborative, multicentre, national trial for newly diagnosed patients with acute lymphoblastic leukaemia (ICICLE-2014)	Dr. Gaurav Narula	Intramural seed & ICMR /NCG	Non-Government	Medical & Health Sciences	2014		

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलपति / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from
 Dean. Academic of various CI's/oc of HBNI.

Prevalence and predictors of malnutrition and its impact on quality of life in patients with Gastric cancer - a single centre prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	2.33	9 Years
Prospective non-randomized study to compare accuracy of clinical examination under anesthesia, axillary ultrasound and histo-pathological examination for axillary nodal staging in women with clinically NO early breast cancer.	Dr. Shalaka Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	.44	8 Years 6 Months
Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	3.92	9 Years
Utility of pectoralis major myofascial flap in reducing pharyngocutaneous fistula rates after salvage total laryngectomy.	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	3.16	9 Years
Phase III randomized trial of high dose chemoradiation and systemic chemotherapy vs systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	11.73	9 Years
Survivorship programme for colorectal cancers patients- a randomized study	Dr. Avanish Saklani	MERCK Specialties PVT LTD	Non-Government	Medical & Health Sciences	2015	3.13	8 Years
A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	28.25	8 Years
Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome	Dr. Vikas Ostwal	MERCK PVT LTD	Non-Government	Medical & Health Sciences	2015	4.96	8 Years
Conventional Radiography based Intracavitary Brachytherapy (Standard Arm) versus Magnetic Resonance Image based BrAchyTherapy (Study Arm) in Locally Advanced Cervical Cancers: A Phase III Randomized Controlled Trial (COMBAT - Cervix Trial)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	16.27	9 Years
Post-Mastectomy Radiation Therapy in High Risk, Node Negative women with Early Breast Cancer (PMRT-NNBC)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	13.31	12 Years
Radiation Dose Optimization in Diffuse large B- cell Lymphoma - A Randomised Phase III non- inferiority trial.	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.36	8 Years
Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tumour tissues of cancer patients: a prospective in-vivo study	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	66.36	6 Years
Assessment of changes in hypoxia related biomarkers during surgery in resectable non-small cell lung cancer	Dr. Sabita Jiwnani	DAE-TMH TRANSCRIPTOME SEQUENCING STUDY PLAN 2712	Non-Government	Medical & Health Sciences	2016	5.16	7 Years
Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice	Dr. Manju Sengar	DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd	Non-Government	Medical & Health Sciences	2016	4.08	8 Years

Compilation of data as received from
Dean - Academics of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
जुलसचिव / REGISTRAR
4.08
होमि भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अनुशाकती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094


Perioperative therapy (preop chemo v/s CRT) in locally advanced gall bladder cancers (POLCA-GB)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.79	8 Years
Performance of HPV DNA Test in presence of co-infection with common RTIs	Dr. Sharmila Pimple	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	1.03	6 Years 6 Months
Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Toxicity and Patient Reported Outcome Measures.	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	5.11	8 Years
Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India	Dr. Jyoti Bajpai	Access Devices	Non-Government	Medical & Health Sciences	2016	1.88	8 Years
Metronomic Adjuvant Chemotherapy Evaluation in locally advanced oral cancers post surgery and appropriate adjuvant therapy	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.63	8 Years
Image Texture Analysis in assessing tumour heterogeneity: A tool to predict, prognosticate cancers and individualize radiotherapy.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	12.21	8 Years
Low Cost Companion Diagnostic Test for Predicting Benefit of Adjuvant Chemotherapy in ER+ Breast Cancer	Dr. Sangeeta Desai	DST (Indo US, Endowment Fund)	Non-Government	Medical & Health Sciences	2016	20.41	7 Years
A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study)	Dr. C. S. Pramesh	TATA TRUST	Non-Government	Medical & Health Sciences	2016	156.03	10 Years
Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes."	Dr. Jyoti Bajpai	Roche Pvt. Ltd	Non-Government	Medical & Health Sciences	2017	.88	7 Years
Study of the Nephron Sparing Surgeries done at Tata Memorial Hospital	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	.04	9 Years
A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B infection (OHBI).	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	.31	8 Years
Protocol No. - NA : Image guided intensity modulated External beam Radiotherapy and MRI based adaptive Brachytherapy in Locally advanced Cervical Cancer. EMBRACE-II	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	5.36	9 Years
Efficacy of Bortezomib and Rituximab in newly diagnosed adolescent and adult CD20 positive Philadelphia (Ph) negative Precursor B-cell acute lymphoblastic leukemia: Phase II study	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	13.82	6 Years
Clinicohistopathological correlation of esthesioneuroblastoma and assessment of prognostic impact of expression of apoptosis markers cleaved Caspase 3, XIAP, Survivin and proliferative marker Ki-67	Dr. Asawari Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	1.36	6 Years 6 Months
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study)	Dr. Reena Engineer	IAEA	Non-Government	Medical & Health Sciences	2016		

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 1. प्रिंसिपल / PRINCIPAL
 2. रेजिस्ट्रार / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from
 Dean-Academic of various CI's/OCC of HBNI.

A Feasibility and Safety Study of Single Application Multifractionated High Dose Rate Brachytherapy in Locally Advanced Cervical Cancer	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	3.72	7 Years
Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma	Dr. Jyoti Bajpai	Roche Products India Pvt. Ltd	Non-Government	Medical & Health Sciences	2016	8.91	7 Years
A prospective COhort study of breast cancer patients with New bone metastases to estimate QQuality of life, health Economics &Risk of skeletal complications (CONQUER)	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	3.96	7 Years
Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco regionally Recurrent or Metastatic Breast Cancer	Dr. Jyoti Bajpai	Eli Lilly and Company India Pvt. Ltd	Non-Government	Medical & Health Sciences	2016	16.61	7 Years
Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study	Dr. Sarbani Ghosh Laskar	IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA)	Non-Government	Medical & Health Sciences	2017	14.33	6 Years 6 Months
A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes	Dr. Sarbani Ghosh Laskar	IAEA	Non-Government	Medical & Health Sciences	2017	1.50	7 Years
Satisfaction in Patients on Outpatient Radiation Therapy (SPORT study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	.10	6 Years 3 Months
DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients,Unsuitable for cisPlatin based cHemoradiation	Dr. Vijay Patil	ICON	Non-Government	Medical & Health Sciences	2017	4.93	12 Years
A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SELECT)	Dr. Anant Ramaswamy	TERRY FOX	Non-Government	Medical & Health Sciences	2017	8.23	7 Years 6 Months
A comparison of clinicopathological profile of non-B non-C hepatocellular cancer (HCC) and Hepatitis B or C related HCC	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	.03	7 Years
A randomized trial to compare gefitinib plus chemotherapy vs chemotherapy alone in EGFR positive and T790M mutation negative advanced Non-small cell lung cancer patients after progression on first line gefitinib.	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	6.36	5 Years
Protocol No. - GBR 200-301 : A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Glven In Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer	Dr. Shalaka Joshi	ALKEM LABORATORIES LTD	Non-Government	Medical & Health Sciences	2017	8.83	6 Years 6 Months


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-
 Academics of various CI's/Occ of HBNI.

A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients.	Dr. Pankaj Chaturvedi	ACTORIUS INNOVATIONS AND RESEARCH PVT LTD.	Non-Government	Medical & Health Sciences	2017	.52	6 Years 6 Months
Effect of Pre Operative Distress Levels on Post Surgical Wound Healing in Head Neck Squamous Cell Carcinoma Patients	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	.65	5 Years
BIONIC: Big Imaging Data Approach For Oncology in a Netherlands India Collaboration	Dr. Venkatesh Rangarajan	DEITY-Dept of Electronics Govt of India	Non-Government	Medical & Health Sciences	2017	8.85	8 Years
Clinicopathologic Features of Undifferentiated Round CellSarcomas of Bone and Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	1.47	5 Years 6 Months
Reverse swing-M : Repurposing of Mebendazole in recurrent glioblastoma.	Dr. Nandini Menon	Brain Tumor Foundation, ICON CRSF, ICMR	Non-Government	Medical & Health Sciences	2017	8.00	6 Years
A randomized study to compare gefitinib with bevacizumab vs gefitinib in EGFR mutation positive Non-small cell lung cancer in palliative setting.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	64.92	5 Years
"Advancing Cancer-care through CANScripT TM Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScripT TM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer"	Dr. Shripad Banavali	Mitra Biotech Pvt. Ltd, Bangalore	Non-Government	Medical & Health Sciences	2018	33.62	6 Years
A cross-sectional feasibility study of a telephonic questionnaire by research nurses for follow-up of locally advanced cervical cancer patients with complete response to treatment	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	.64	6 Years
Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor	Dr. Sudhir Vasudevan Nair	NATIONAL CANCER GRID	Non-Government	Medical & Health Sciences	2018	5.13	6 Years
Evaluating the clinical utility of new immunophenotypic markers in the determination of minimal residual disease in childhood acute myeloid leukemia.	Dr. Prashant Tembhare	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	.67	6 Years
Pilot study to evaluate the biodistribution & dosimetry of ¹⁷⁷ Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	20.50	6 Years
CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQuenCE)	Dr. Shalaka Joshi	IM / CSR Fund from Gen. Insu. Co.	Non-Government	Medical & Health Sciences	2018	19.44	10 Years

Compilation of data as received from
Dean-Academic of various CI'S/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - MO29872 : A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy	Dr. Kumar Prabhash	Roche Products (India) Pvt. Ltd	Non-Government	Medical & Health Sciences	2017	33.18	6 Years 4 Months
A dosimetric and clinical study of DIBH in Mediastinal Lymphomas: An exploratory observational study	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	4.07	14 Years
Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer	Dr. Archi Agrawal	IAEA	Non-Government	Medical & Health Sciences	2018	3.02	4 Years 6 Months
Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	1.13	6 Years
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	10.20	6 Years
Protocol No. - I3Y-MC-JPCF : A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE)	Dr. Seema Gulia	Eli Lilly and Company India Pvt. Ltd.	Non-Government	Medical & Health Sciences	2018	21.73	10 Years
A randomized clinical trial evaluating the efficacy and safety of the addition of postoperative chemoradiation versus observation in patients with high-risk esophageal squamous cell carcinoma following surgery	Dr. Devayani Niyogi	CREST Welfare Fund	Non-Government	Medical & Health Sciences	2019	25.03	12 Years
Protocol No. - D419CC00002 : A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2018	10.24	4 Years
A Phase 2 randomized controlled trial to evaluate the role of modified C.O.M.B.A.T maintenance regimen in children with high risk medulloblastoma	Dr. Girish Chinnaswamy	Terry Fox foundation	Non-Government	Medical & Health Sciences	2018	11.68	5 Years
Precision medicine and Malnutrition- A Model based approach to dose chemotherapy in pediatric patients with malnutrition	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Sciences	2018	28.82	6 Years
Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival.	Dr. Vikas Ostwal	Intramural and Extramural grant-unrestricted educational grant from Cadila healthcare limited	Non-Government	Medical & Health Sciences	2018	2.91	6 Years
A randomized phase 2/3 trial of Rosuvastatin with neo-adjuvant chemo-radiation in patients with rectal cancer	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	17.74	7 Years

Handwritten signature/initials in green ink.

Compilation of data as received from Dean - Academics of various CI's/Occ of HBNI.

Introduction of a novel, cost effective, multigene panel for NSCLC patients - A pilot project	Dr. Rajiv Kumar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	34.48	6 Years
Effect Of Pre-Operative Transarterial Embolisation On Circulating Tumor Cells And Recurrence In Hepatocellular Carcinoma	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.43	4 Years
Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4	Dr. Ashish Gulia	Non-ferrous Materials Technology Development Centre, Hyderabad	Non-Government	Medical & Health Sciences	2019	85.58	5 Years
Protocol No. - WO40242 : A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck	Dr. Kumar Prabhash	Roche Products (India)	Non-Government	Medical & Health Sciences	2018	20.25	7 Years
Protocol No. - SII-qHPV/IN-02 : A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)	Dr. Sharmila Pimple	Serum Institute of India Pvt. Ltd, Hadapsar, Pune (Sponsor)	Non-Government	Medical & Health Sciences	2018	24.95	5 Years 9 Months
Protocol No. - 19214 : A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC)	Dr. Vikas Ostwal	Bayer AG, D-51368 Leverkusen, Germany	Non-Government	Medical & Health Sciences	2018	14.58	6 Years
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation	Dr. Kumar Prabhash	Oncology Care Associates, ICON Trust	Non-Government	Medical & Health Sciences	2018	3.85	8 Years
Feasibility Of Magnetic Resonance Image Based Target Delineation In Radical High Dose Rate Interstitial Brachytherapy For Early Oral Cavity Cancers: A Pilot Study	Dr. Ashwini Budrukhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	.28	5 Years
Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients.	Dr. Sudeep Gupta	HLL Lifecare Limited	Non-Government	Medical & Health Sciences	2018	9.94	5 Years
Prospective cohort study to determine the association of pre-operative nutritional status with 90 days morbidity among patients undergoing Radical cystectomy or Radical Cysto-Prostatectomy for Muscle Invasive Bladder Cancer	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.01	7 Years 6 Months
Carboplatin/paclitaxel versus cisplatin/5-fluorouracil definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	3.37	10 Years

Compilation of data as received from
Dean-Academic of various CI's/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Sudeep Gupta	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India	Non-Government	Medical & Health Sciences	2018	48.93	5 Years
Pilot Study to standardize the technique of Dynamic Sentinel Lymph Node Biopsy in management of penile cancer patients with clinically normal groin	Dr. Gagan Prakash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.97	4 Years
Biomarker-based optimization of adjuvant therapy in glioblastoma	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	54.18	5 Years
A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1)	Dr. Supriya Chopra	BIOEMBRACE RESEARCH GROUP	Non-Government	Medical & Health Sciences	2019	4.72	5 Years
Two arm, triple blinded, randomized placebo controlled, prospective, parallel design Phase II integrated phase III study to evaluate the role of Carica papaya leaf extract (CPL) in reducing the duration of chemotherapy induced thrombocytopenia and adverse events related to thrombocytopenia	Dr. Vikas Ostwal	CADILA HEALTHCARE LIMITED	Non-Government	Medical & Health Sciences	2019	7.56	5 Years 6 Months
A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cytorreduction in pediatric AML patients presenting with hyperleukocytosis	Dr. Shripad Banavali	SOHN FOUNDATION THROUGH GRAVIS	Non-Government	Medical & Health Sciences	2018	4.72	5 Years
Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India	Dr. Deepa Nair	Case Western University, cleaveland	Non-Government	Medical & Health Sciences	2018	1.64	5 Years 6 Months
A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma.	Dr. Sudhir Vasudevan Nair	Tata Trusts, Vigilant Biosciences	Non-Government	Medical & Health Sciences	2018	3.41	5 Years
A Pilot Study of CONcurrent ChEmotherapy and RadioTherapy in Adjuvant Treatment of Breast Cancer (CONCERT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	1.33	5 Years
Protocol No. - CACZ885T2301 : A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIa and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Dr. Vijay Patil	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2019	12.72	7 Years
Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III randomized trial (RAPPAL Study)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	14.30	5 Years
Inflammatory Indices in Diffuse Glioma (InDiGo): A Prospective Observational Study	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	.60	6 Years
Human cancer pathology atlas (HCPA) & Machine learning and Artificial intelligence in Pathology (MAP)	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	294.87	5 Years

Compilation of data as received from
Dean-Academics of various CI's/OCC of HBNI.

Androgen blockade - Is this the missing link between mucinous micro-papillary carcinoma and micro-papillary carcinoma of breast.	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	8.11	5 Years
A Prospective Randomised trial to assess the clinical utility of TMH Mini Quality of Life (TMQ) questionnaire	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.60	4 Years
Early detection programme for Oral, Breast and Cervical Cancer in Sangrur district of Punjab State	Dr. Atul Budukh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	31.14	5 Years 6 Months
A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB)	Dr. Anant Ramaswamy	Zydus Non-Governmentceuticals, Dr. Reddy's Laboratories Limited	Non-Government	Medical & Health Sciences	2019	3.14	5 Years
Clinical effect of vaporized CAnnabinoids on BReast cancer genetic EXpression patterns in the peri-operative period (CABREX study)	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	17.17	4 Years
A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse Intrinsic Pontine Glioma. (LoBULaR-DIPG)	Dr. Rahul Krishnatry	Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND	Non-Government	Medical & Health Sciences	2019	3.90	4 Years
Protocol No. -0328-17 : A single arm, multicentric, open label, efficacy and safety study of Docequalip (Docetaxel Lipid Suspension for Injection of Intas Non-Governmentceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients	Dr. Vikas Ostwal	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India.	Non-Government	Medical & Health Sciences	2019	23.51	3 Years 10 Months
A phase II study of hormone therapy alone in low-grade serous cancer (ovary/fallopian tube/peritoneum) following debulking surgery	Dr. Seema Gulia	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	4.25	6 Years
Prevalence of cardiovascular diseases in long term Breast Cancer survivors	Dr. Sheela Sawant	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.44	6 Years
A prospective observational cohort study to identify the utility of risk-based screening strategy for long term complications in adolescent and adult cancer survivors of leukemia and lymphoma.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	6.50	5 Years
Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer	Dr. Sudeep Gupta	Eirgenix Inc.	Non-Government	Medical & Health Sciences	2019	66.00	4 Years
Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery	Dr. Gouri Pantvaidya	TERRY FOX	Non-Government	Medical & Health Sciences	2019	6.02	5 Years
Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach	Dr. Sharayu Mhatre	ASCO (American Society of Cancer Oncology)	Non-Government	Medical & Health Sciences	2019		

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेलिन / Prof. P. C. Selin
REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

for Prognosis and Prediction in Breast Cancer Patients subjected to adjuvant therapy.	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	4.30	5 Years
Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma	Dr. Tejpal Gupta	NRG Oncology/RTOG	Non-Government	Medical & Health Sciences	2019	1.10	12 Years
Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police, , Railway Police, Maharashtra Police and Maharashtra Security Force.	Dr. Gauravi Mishra	DAECTC + Tata Trusts	Non-Government	Medical & Health Sciences	2019	148.04	5 Years
A Prospective Phase III open label Randomized Controlled Trial evaluating the role of Neo-adjuvant chemotherapy in mandible preservation in oral cavity cancers	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	62.93	6 Years
Neoadjuvant treatment versus upfront surgery in Resectable pancreatic cancer (NEVUS)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	14.88	5 Years
A double arm, phase-III randomised study to assess the effect of Resveratrol-Copper in reducing oral mucositis in patients receiving concurrent chemo-radiotherapy for locally advanced oral cavity and oropharyngeal cancers	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	10.31	5 Years
A Prospective Randomized Phase III Trial of Short Course Versus Long Course Local Radiotherapy in patients with Multiple Myeloma symptomatic for Pain (ProM)	Dr. Nehal Khanna	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	13.59	6 Years
PRCedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.00	8 Years
COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA	Dr. Prachi Mittal	CRDF Global-ICMR	Non-Government	Medical & Health Sciences	2019	20.76	4 Years
Effect of nurse led intervention on cognitive and non-cognitive functions and serum TNF alpha levels in patients receiving chemotherapy for CRC at Tata Memorial Hospital, Mumbai	Mrs. Anita D Souza	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.53	4 Years 6 Months
Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre (EXPERT).	Dr. Tabassum Wadasadawala	WCI-NAG foundation	Non-Government	Medical & Health Sciences	2019	2.00	5 Years
Neuropathic pain in head and neck cancer patients referred to Specialist Palliative Care services: a cross sectional observational study.	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	.02	3 Years
Classical Hodgkins lymphoma(CHL) with primary marrow presentation- does it use immune escape mechanism to hide ?	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	6.12	1 Years
Randomised Trial comparing efficacy of Prophylactic versus Reactive Enteral Tube Insertion for Enteral Nutrition in Patients with Locally Advanced Head and Neck Carcinoma Treated with (Chemo)radiotherapy	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	5.23	5 Years

Compilation of data as received from Dean-Academics
of various CI's/OCC of HBNI.

Prevalence and impact of Vitamin D deficiency on the treatment outcomes of Head and Neck squamous cell carcinoma patients. Protocol No. - D933GC00001 : A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	7.50	4 Years
Evaluation of Organ filling (rectum and bladder) and Comprehensive Adaptive Radiotherapy using daily imaging by CBCT during radical radio(chemo)therapy for locally advanced cervical cancers.	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2019	14.43	4 Years
Protocol No. - CLEE011A3201C : A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	8.78	4 Years
A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients-TARGET-1	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2020	90.20	5 Years
A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	9.39	6 Years
Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial)	Dr. Shiva Kumar Thiagarajan	ICON	Non-Government	Medical & Health Sciences	2019	2.50	4 Years
Intra-operative recurrent laryngeal nerve monitoring during three field esophagectomy- a pilot study	Dr. Vikas Ostwal	Intramural and extramural grant (educational grant from Dr. Reddy' s limited	Non-Government	Medical & Health Sciences	2019	90.76	5 Years
Protocol No. - 20160372 : Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.98	4 Years
Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer	Dr. Bhausheeb Bagal	Amgen Inc	Non-Government	Medical & Health Sciences	2019	27.33	4 Years 11 Months
A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India	Dr. Kumar Prabhash	Eisai Non-Governmentceuticals India Pvt. Ltd.	Non-Government	Medical & Health Sciences	2019	7.55	4 Years 1 Months
	Dr. Rajesh Dikshit	Clinton Health Access Initiative (CHAI), USA	Non-Government	Medical & Health Sciences	2019		

rebut

प्रो. पी. सी. सेल्विन / Prof. P. C. Salvin
कुलसचिव / REGISTRAR
469
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

Primary screening of high risk HPV DNA by a low cost molecular HPV test for early detection of cervical precancers and cancers among women in urban and rural community of Maharashtra	Dr. Sharmila Pimple	Department of Health Research (DHR)	Non-Government	Medical & Health Sciences	2019	23.14	4 Years
HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study)	Dr. Sheila Myatra	ISCCM	Non-Government	Medical & Health Sciences	2019	.40	2 Years 6 Months
Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).	Dr. Kumar Prabhash	ALKEM LABORATORIES LIMITED	Non-Government	Medical & Health Sciences	2019	41.95	3 Years 10 Months
Protocol No. - QB46C-H03 : Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours	Dr. Gouri Pantvaidya	QBiotics Group Limited (QBiotics)	Non-Government	Medical & Health Sciences	2019	17.67	4 Years
Protocol No. - CLEE011A2207 : A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2020	22.08	4 Years
Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions.	Dr. Sharmila Pimple	Periwinkle Technologies Pvt. Ltd., Pune	Non-Government	Medical & Health Sciences	2019	2.23	3 Years
Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India	Dr. Sudeep Gupta	Glenmark Non-Governmentceuticals Ltd.	Non-Government	Medical & Health Sciences	2020	4.17	2 Years 6 Months
Carboplatin / Paclitaxel Versus Cisplatin/ Etoposide as Definitive Chemoradiotherapy for LocoRegionally advanced Non small Lung cancer (NSCLC): A Phase III Randomized Controlled Trial	Dr. Ajaykumar Singh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.07	11 Years
Total Marrow and Lymphoid Irradiation (TMLI) as conditioning regimen for peripheral stem cell transplant in high risk/ relapsed /refractory leukemias.	Dr. Jayant Goda	Terry Fox	Non-Government	Medical & Health Sciences	2019	12.26	5 Years
Clinical outcome of common cancers treated with radical intent at HBCH Sangrur- A Retrospective Analysis	Dr. Jai Prakash Agarwal	University of Pennsylvania Philadelphia, US	Non-Government	Medical & Health Sciences	2019	8.25	2 Years

Compilation of data as received from Dean-
Academics of various CI's/OCC of HBNI.

Phase 1 study of safety and feasibility of Ayurvedic oral cannabis preparation in the peri-operative period in breast and oral cavity squamous cell cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	41.02	2 Years
Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors	Dr. Rajendra Badwe	Trilokchand Papriwal Charitable Trust	Non-Government	Medical & Health Sciences	2020	66.26	5 Years
A two arm randomized open label prospective design superiority Phase II - III clinical trial to compare the efficacy of Docetaxel-oxaliplatin-capecitabine/ 5 fluorouracil (DOC/F) followed by Docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in advanced Gastric Cancers (DOC-GC)	Dr. Anant Ramaswamy	ASTRAZENECA Non-Government IND LTD / MERCK SPECIALITIES PVT LTD / DR. REDDYS LAB LTD / ELI LILLY AND COMP IND PVT LTD / ICON TRUST / NAG FOUNDATION / MANKIND Non-Government LTD	Non-Government	Medical & Health Sciences	2020	21.87	4 Years 6 Months
Protocol No. - MK3475-593 : A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Dr. Jyoti Bajpai	MSD Non-Governmentceuticals Pvt Ltd	Non-Government	Medical & Health Sciences	2020	91.22	5 Years
An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients	Dr. Sridhar Sundaram	EISAI Non-Government CEUTICALS, INTAS	Non-Government	Medical & Health Sciences	2020	6.39	6 Years
Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Dr. Vikas Ostwal	Dr. Reddy's Laboratories Ltd.	Non-Government	Medical & Health Sciences	2020	8.96	3 Years
Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification ; A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)	Dr. Anant Ramaswamy	Educational Grant - Reliance Life Science / DAECTC	Non-Government	Medical & Health Sciences	2020	1.60	7 Years
A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.24	5 Years
A phase II study to evaluate the role of short-course Pomalidomide in maintaining treatment-free remission post tyrosine-kinase inhibitor (TKI) discontinuation in adult patients with chronic myeloid leukemia-chronic phase (CML-CP).	Dr. Hasmmukh Jain	Unrestricted grants educational grants from Non-Government companies	Non-Government	Medical & Health Sciences	2020	33.38	6 Years 6 Months

Compilation of data as received from
Dean Academic of various CI's/OCC of HBNI.

A clinical study to evaluate the safety and feasibility of outpatient induction therapy in newly diagnosed adolescent and adult acute myeloid leukemia (AML).	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.71	3 Years
A study evaluating the efficacy of axillary reverse mapping in biopsy proven patients undergoing upfront surgery.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	.73	4 Years
A randomized trial to assess the effect of Oral Cryotherapy in prevention of mucositis in head and neck cancer patients receiving Chemo-Radiotherapy	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.36	5 Years
Treatment and monitoring of children and adolescents with Chronic Myeloid Leukemia (CML)- A prospective observational study.	Dr. Nirmalya Moulik	SOHN foundation through GRAVIS	Non-Government	Medical & Health Sciences	2020	3.34	5 Years
Epithelial-mesenchymal transition (EMT) and Breast Cancer Stemness: Defining the role of OVOL and ACTN4 in cross talk	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	8.71	3 Years
Grid Oncology: Remaking Cancer Care in India	Dr. C. S. Pramesh	Wellcome Trust	Non-Government	Medical & Health Sciences	2020	7.59	4 Years
Study of the excess cost associated with drug wastage due to limited vial size options of the intravenous drugs for anti-cancer treatment, among patients receiving such treatment at Tata Memorial Hospital - 'CADWIACT' study	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	.17	3 Years 6 Months
An open label, randomized, clinical trial of Mycobacterium w (Mw) as an Adjuvant to chemotherapy in Advanced Non-small Cell Lung Cancer	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	32.44	6 Years
Standard Maintenance Therapy versus Local Consolidation Radiation Therapy and Standard Maintenance Therapy In 1-5 sites of oligometastatic Non-Small Cell Lung Cancer (NSCLC) - A Phase III Randomized Controlled Trial (TARGET-2)	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	10.13	6 Years
To assess the efficacy of low dose Abiraterone (250 mg (1 tablet) once daily taken along with food) in comparison to the standard dose Abiraterone (1000 mg (4 tablets) taken in fasting state) in patients with Metastatic Castrate Resistant Prostate Cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	7.27	5 Years
A Prospective Observational Study on Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.56	5 Years
A prospective study to assess the effect of peri operative administration of oral Resveratrol and copper(R- Cu) on survival in Glioblastoma (GBM) patients.	Dr. Aliasgar Moiyadi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.53	5 Years
Indian Pulmonary Embolism Registry (IndiPER)	Dr. Sohan Solanki	ETERNAL HOSPITAL JAIPUR	Non-Government	Medical & Health Sciences	2020	.05	3 Years
A randomized, open label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with standard triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy induced Nausea and vomiting in subjects with osteosarcoma and other solid tumors (OLAnzaPINE)	Dr. Jyoti Bajpai	PROGRESSIVE LADIES WELFARE SOCIETY (NGO)	Non-Government	Medical & Health Sciences	2020	1.32	4 Years

Compilation of data as received from
Dean-Academics of various CI's/OCC of HBNI.

Capecitabine and Erlotinib in advanced Hepatocellular Carcinoma (HCC) after Sorafenib failure (CAPER- HCC study) - a single arm, prospective phase II clinical trial.	Dr. Prabhat Bhargava	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	16.69	2 Years 6 Months
Phase I study to evaluate the feasibility and safety of addition of ruxolitinib to a standard BFM-90 regimen in adolescent/adult Ph-like ALL.	Dr. Hasmukh Jain	EM- LADY TATA MEMORIAL TRUST	Non-Government	Medical & Health Sciences	2020	18.74	4 Years
A study to validate the Multinational Association of Supportive Care in Cancer (MASCC) antiemesis tool for adolescent and adult patients with hematological malignancies receiving chemotherapy.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	.08	3 Years 6 Months
Improving the efficiency of Breath-hold treatment in cancer radiotherapy using 3D goggles: a randomized study	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.44	4 Years
Focal Radiotherapy Plus Low-Dose Craniospinal Irradiation Followed By Adjuvant Chemotherapy In WNT Subgroup Medulloblastoma (FOR-WNT 2 Study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.75	10 Years
Pregabalin for chronic cough in patients with lung cancer: A randomized double-blind placebo-controlled trial.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.19	3 Years
Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases: A phase III Randomized Controlled Trial	Dr. Anil Tibdewal	Intramural and EM-NEUROONCOLOGY RESEARCH FUND	Non-Government	Medical & Health Sciences	2020	14.27	6 Years
Whole brain radiation therapy plus Resveratrol-Copper in brain metastases patients of non small cell lung cancer - A Phase II Randomized controlled trial.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	7.34	6 Years 6 Months
Protocol No. - D0816R00025 : A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2020	49.22	3 Years
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Government	Medical & Health Sciences	2020	58.12	2 Years
Genomic Profiling of SARS-CoV-2 Infection in the city of Mumbai	Dr. Nikhil Patkar	ACTREC	Non-Government	Medical & Health Sciences	2020	8.77	2 Years
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2020	136.38	4 Years 4 Months
Seroprevalence of COVID-19 in slum and non slum areas of Mumbai	Dr. Rajesh Dikshit	i-spirit	Non-Government	Medical & Health Sciences	2020		

Compilation of data as received from
Dean-Academic of various CI's/Occ of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Intravesical BCG: is the urinary bladder ready to receive it?	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	10.79	2 Years
A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma	Dr. Manju Sengar	TRAC and Unrestricted Educational grants from Non-Government companies AND DONORS	Non-Government	Medical & Health Sciences	2020	34.91	4 Years
A pilot study of indigenously manufactured HCAR19 (2nd generation Anti-CD19-41BBCD3 (zeta) chimeric antigen receptor T-cell therapy) in adult patients with relapsed/refractory diffuse large B-cell lymphoma.	Dr. Hasmukh Jain	Intramural and Extramural-Immunoadoptive cell therapy private limited, ICMR	Non-Government	Medical & Health Sciences	2020	7.95	9 Years 11 Months
Angiotensin receptor blockade with losartan plus mFOLFIRINOX versus mFOLFIRINOX alone in advanced Pancreatic AdenoCarcinomas - a two arm open label prospective Phase III parallel design randomized superiority clinical trial (AFPAC)	Dr. Anant Ramaswamy	EM - LUPIN PVT LTD	Non-Government	Medical & Health Sciences	2021	4.85	7 Years
PIK3CA Registry- A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer.	Dr. Sudeep Gupta	NOVARTIS HEALTHCARE PRIVATE LIMITED	Non-Government	Medical & Health Sciences	2020	4.88	2 Years
Prospective study to evaluate which method of estimated GFR best predicts for measured GFR in patients with ovarian cancer undergoing carboplatin based chemotherapy	Dr. Jaya Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	.79	3 Years
A Double Blind Placebo Controlled Randomized Trial On Oral Cannabis For Chronic Cancer Pain Relief	Dr. Aparna Chatterjee	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	4.98	2 Years
Posterior fossa Ependyomas: a study on molecular subgrouping Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	13.99	2 Years
	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2020	29.65	4 Years
A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC)	Dr. Vikas Ostwal	Eisai Non-Governmentceuticals, India Pvt. Ltd. 6th Floor, A Wing, Marwah Center, Krishanlal Marwah Marg, Andheri East, Mumbai 400072. Maharashtra, INDIA. Phon	Non-Government	Medical & Health Sciences	2021	3.13	3 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

Influence of Preoperative Vitamin-D, Serum Magnesium and Serum Phosphate levels on the development of transient and permanent hypocalcaemia and hypoparathyroidism following total thyroidectomy with or without central compartment clearance in patients with thyroid cancer (HypoCal Study).	Dr. Shiva Kumar Thiagarajan	RESEARCH A/C 4254	Non-Government	Medical & Health Sciences	2020	4.58	4 Years
Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Dr. Jigeeshu Divatia	The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga	Non-Government	Medical & Health Sciences	2020	3.00	2 Years
Primary Surgery versus Primary Chemo-radiation for Oropharyngeal Cancer (SCOPE trial) - A Phase II/III Integrated Design Randomized Control Trial	Dr. Deepa Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	22.81	6 Years 11 Months
A Randomized Study to compare Gefitinib to Gefitinib with Chemotherapy in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients with Compromised Performance Status.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	27.16	4 Years
Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer.	Dr. Vikas Ostwal	Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, Enzene Biosciences Limited, Plot Number	Non-Government	Medical & Health Sciences	2021	4.39	3 Years 4 Months
Protocol No. - D133HC00003 : A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)	Dr. Nandini Menon	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	22.76	3 Years 6 Months
Protocol No. - D9106C00001 : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)	Dr. C. S. Pramesh	AstraZeneca AB	Non-Government	Medical & Health Sciences	2021	9.50	7 Years
Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study	Dr. Hasmukh Jain	Hematology Cancer Consortium	Non-Government	Medical & Health Sciences	2021	4.22	3 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशासन विद्यालय परिसर, अणुशक्ति नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - 61186372NSC3001 : A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Dr. Vanita Noronha	Johnson and Johnson Private Limited	Non-Government	Medical & Health Sciences	2021	22.79	3 Years 6 Months
TMH IRIS: Proposal for participation of TMH ICU in the Indian Registry of IntenSive care (IRIS)	Dr. Atul Kulkarni	Chennai Critical Care Consultants Group	Non-Government	Medical & Health Sciences	2021	.22	12 Years
Protocol No. - 73841937NSC3003 : A Phase 3, Randomized study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated LocallyAdvanced or Metastatic Non-Small Cell Lung Cancer	Dr. Kumar Prabhash	Johnson & Johnson Private Limited	Non-Government	Medical & Health Sciences	2021	32.60	3 Years 6 Months
A Phase 4 Study of Nivolumab in Combination with Ipilimumab in Patients with PreviouslyUntreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk FactorsConducted in India	Dr. Amit Joshi	Bristol-Myers Squibb Research and Development	Non-Government	Medical & Health Sciences	2021	33.69	3 Years
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)	Dr. Swapnil Rane	NIH	Non-Government	Medical & Health Sciences	2021	26.19	5 Years
Prophylactic pirfenidone for prevention of radiation induced pneumonitis in patients with Lung cancer (PROPER study)	Dr. Naveen Mummudi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	.33	3 Years
PIK3CA mutation prevalence and clinico-pathological association in breast carcinomas	Dr. Sangeeta Desai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	7.01	2 Years 6 Months
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2021	22.19	3 Years
CDKN2A deletion in IDH-mutant diffuse astrocytic tumors	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.36	2 Years
Evaluating Immunohistochemical and Molecular Landscape of Select Osteoclastic Giant Cell Rich Tumors of the Bone	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	4.13	3 Years
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2021	6.24	3 Years
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)	Dr. C. S. Pramesh	Astrazeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	12.61	6 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.


Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital	Mrs. Anita D Souza	IASCC	Non-Government	Medical & Health Sciences	2021	.80	3 Years
Early T-cell precursor acute lymphoblastic leukaemia: Unravelling mechanisms of resistance and development of novel therapeutic strategies	Dr. Manju Sengar	Lady Tata Memorial Trust	Non-Government	Medical & Health Sciences	2021	49.46	4 Years
Effect of topical coconut oil application versus standard supportive care on xerostomia related quality of life among patients with radiation induced xerostomia in H& N cancer patients in tertiary care cancer center- A randomized control trial	Mrs. Meera Achrekar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	.20	3 Years 10 Days
Enhanced Recovery Pathway in Head and Neck Cancer Surgery	Dr. Vandana Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.47	3 Years
National Quality Assurance (NQA) program in Biochemistry for Electrophoresis, Immunofixation and Tumor markers in centers of the National Cancer Grid	Dr. Kinjalika Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	20.17	3 Years
A phase I study of oral metronomic capecitabine with cyclophosphamide as maintenance therapy in patients with chemotherapy responsive advanced colorectal cancers .	Dr. Anant Ramaswamy	RESEARCH A/C 4254	Non-Government	Medical & Health Sciences	2021	22.62	2 Years 6 Months
Protocol No. - D967JC00001 : A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Dr. Sudeep Gupta	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2021	48.05	3 Years
PROspecTive Study on the use of gEriatriC assessment Tools for validation of 1-year mortality in breast cancer patients 65 years and older (PROTECT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	3.40	3 Years
Avoiding prophylactic growth factors during paclitaxel phase of dose dense adjuvant chemotherapy in breast cancer	Dr. Seema Gulia	Indian Association of Supportive Care	Non-Government	Medical & Health Sciences	2021	1.50	2 Years
Assessment of the Breast Cosmesis using Deep neural networks: an exploratory study (ABCD)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	17.37	3 Years
Pilot study for measurement of intra-tumoral interstitial fluid pressure in various cancers	Dr. Shalaka Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	17.92	3 Years
Arsenic trioxide (ATO) plus FOLFIRI vs. Irinotecan monotherapy as second-line therapy in advanced Colorectal Cancers - a randomized non-blinded two-arm Phase II prospective (ATaCC study).	Dr. Prabhat Bhargava	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	7.59	5 Years
Prevalence, predisposing factors and management of Head and Neck Lymphedema in patients following treatment for Head and Neck Cancer. (HeNly-1 Study)	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.06	4 Years

Compilation of data as received from
Dean - Academic of various CI's/oc of HBNI.


प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - D9311C00001 : A Randomised, Multicentre, Double blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Dr. Sudeep Gupta	AstraZeneca	Non-Government	Medical & Health Sciences	2021	50.21	4 Years
An open label phase III randomized clinical trial of pomalidomide cyclophosphamide and dexamethasone versus pomalidomide dexamethasone in relapsed/ refractory multiple myeloma treated with lenalidomide and a proteasome Inhibitor.	Dr. Lingaraj Nayak	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.51	3 Years 10 Months
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Dr. Badira Parambil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.35	10 Years
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	Dr. C. S. Pramesh	Astrazeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	8.48	7 Years 6 Months
The Clinical Value of Ultrasound based Navigation update in cranial resection procedures	Dr. Aliasgar Moiyadi	Brainlab AG	Non-Government	Medical & Health Sciences	2021	11.08	3 Years
Pilot testing of Hindi and Marathi translations of the European Organization for the Research and Treatment of Cancer (EORTC) module, assessing quality of life in patients with primary vulva cancer (EORTC QLQ VU34).	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	.05	2 Years
A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors(NAVIGATE)	Dr. Vikas Ostwal	Non-US: Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, Switzerland US-territory: Bayer HealthCare Non-Governmentceuticals Inc., 100 Bayer Boule	Non-Government	Medical & Health Sciences	2021	17.08	3 Years
A randomized phase III clinical trial evaluating the non-inferiority of reduced dose chemotherapeutic regimens based on CARG risk scores compared to standard doses in Older patients with advanced esophageal, esophagogastric, gastric, and biliary tract cancers (CARGO study)	Dr. Anant Ramaswamy	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	10.02	6 Years

Compilation of data as received from
Dean - Academic of various CI's/oc of HBNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Preventing Cervical Cancer in India through self-sampling (PCCIS)	Dr. Gauravi Mishra	Fund for Innovation and Transformation, program of the Inter-Council Network of Provincial and Regional Councils (ICN), Global Affairs Canada.	Non-Government	Medical & Health Sciences	2021	43.96	1 Years 9 Months
Protocol No. - D8220C00022 : A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acabrutinib capsules in Indian adult patients with chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma	Dr. Manju Sengar	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	14.72	2 Years
Impact of on-demand training & audio-visual aids to improve referral rates for genetic counselling and/ testing at a tertiary cancer centre (Mainstreaming Study)	Dr. Rima Pathak	Astra Zeneca	Non-Government	Medical & Health Sciences	2022	5.00	2 Years
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients with Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer	Dr. Kumar Prabhaskar	Astra Zeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2022	1.50	2 Years
Immunohistochemical analysis of LLT1 on prostate cancer biopsy samples	Dr. Santosh Menon	Zumutor Biologics	Non-Government	Medical & Health Sciences	2021	2.29	2 Years
Women Empowerment-Cancer Awareness Nexus (WE-CAN): An Implementation Research Study of Cervical Cancer Prevention through HPV Self-Sampling and Education in India	Dr. Gauravi Mishra	Indian Medical Council of Research (ICMR) & Canadian Institutes of Health Research (CIHR) under Global Alliances for Chronic Diseases(GACD)	Non-Government	Medical & Health Sciences	2021	314.30	5 Years
An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E Mutant Colorectal Cancer	Dr. Vikas Ostwal	PFIZER	Non-Government	Medical & Health Sciences	2021	20.29	3 Years
PRESCRIP-TEC							
Prevention and Screening Innovation Project Toward Elimination of Cervical Cancer	Dr. Sharmila Pimple	Horizon 2020-DBT	Non-Government	Medical & Health Sciences	2021	25.19	3 Years
Protocol No. - WO42633 : Protocol No. - WO42633 : A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy (ASTEFANIA STUDY).	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd.	Non-Government	Medical & Health Sciences	2022	50.52	10 Years


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमि भबहा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ति नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from
 Dean-Academic of various CI's/OCC of HBNI.

Protocol No. - MO42921 : A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY TO EVALUATE THE PREVALENCE OF PD-L1 AND ITS ROLE IN PATIENTS WITH TNBC TREATED WITH SYSTEMIC THERAPY (VANESSA)	Dr. Sudeep Gupta	Roche Products India Pvt Ltd.	Non-Government	Medical & Health Sciences	2022	13.90	2 Years
Protocol No. - DP-1111-02CT : A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of Gastroenteric or Pancreatic Origin (COMPOSE)	Dr. Venkatesh Rangarajan	ITM Solucin GmbH	Non-Government	Medical & Health Sciences	2022	37.78	2 Years 10 Months 1 Days
Developing precision immunotherapy for value-based treatment of lung cancer in India	Dr. C. S. Pramesh	DBT/Wellcome Trust india Alliance	Non-Government	Medical & Health Sciences	2021	199.82	5 Years
GUT MICROBIOME IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - ASSOCIATION WITH LEUKEMOGENESIS, SERIAL SURVEILLANCE AND EFFECT ON TOXICITY, DISEASE OUTCOME AND IMMUNOLOGICAL RECOVERY	Dr. Nirmalya Moulik	LADY TATA MEMORIAL TRUST	Non-Government	Medical & Health Sciences	2022	34.59	3 Years
Protocol No. - ACE-LY-312(D8227C00001) : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma	Dr. Bhausaheb Bagal	AstraZeneca Canada Inc.	Non-Government	Medical & Health Sciences	2022	22.53	8 Years
Protocol No. - GO42784 : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	Dr. Sudeep Gupta	Hoffmann-La Roche Ltd	Non-Government	Medical & Health Sciences	2022	52.09	10 Years
PERioperative respiratory care and outcomes for patients Undergoing high risk abdominal surgery	Dr. Sohan Solanki	University of Birmingham	Non-Government	Medical & Health Sciences	2022	.90	2 Years
Protocol No. - D0817R00044 : A non-interventional, multicenter study to determine the prevalence of homologous recombination repair (HRR) gene mutation in patients with metastatic castration-resistant prostate cancer in India	Dr. Nandini Menon	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2022	7.50	1 Years 6 Months
Developing a 3D-printed Humanoid Phantom for Breast Cancer Radiotherapy Dosimetry and Quality Assurance	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	.18	2 Years
A Multi-country, Multi-centre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate Cancer.	Dr. Amit Joshi	AstraZeneca	Non-Government	Medical & Health Sciences	2022	8.65	1 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलपति / REGISTRAR
 होमि भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from
 Dean Academic of various CI's/oc of HBNI.

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure	Dr. Ajaykumar Singh	Janssen	Non-Government	Medical & Health Sciences	2022	23.70	3 Years
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Safety And Efficacy Of PolatuzumabVedotin In Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-Gemox) Versus R-Gemox Alone In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Dr. Manju Sengar	Roche Products (India) Private Limited	Non-Government	Medical & Health Sciences	2022	9.92	3 Years
Molecular profiling of malignant brain tumors using CSF derived circulating tumor DNA	Dr. Tejpal Gupta	Strand Life Sciences Pvt. Ltd.	Non-Government	Medical & Health Sciences	2022	4.62	2 Years
Protocol No. - D419CR00025 : A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma	Dr. Vikas Ostwal	Sponsor : AstraZeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2022	1.12	2 Years
Identifying potentially metastatic cells in primary tissue by identifying specific proteins associated with these phenotypes using an antibody library based screening of TNBC.	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	31.87	2 Years
Protocol No. - D967SC00001 : An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	Dr. Nandini Menon	Astrazeneca Pvt Ltd	Non-Government	Medical & Health Sciences	2022	10.34	6 Years
Multiparametric brain mapping integrating structural, functional and biological features and correlation with functional and oncological outcomes (BrainMap Study)	Dr. Aliasgar Moiyadi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	73.30	3 Years
Prospective PeriOperative study Evaluating Routine Coagulation versus Thromboelastography for Liver resections (PORTAL 2 Trial)	Dr. Reshma Ambulkar	TRAC (TMC research administration council)	Non-Government	Medical & Health Sciences	2022	.99	1 Years
Validation of the Caregiver Burden Scale & assessment of caregiving burden of parents of children with advanced cancer at a tertiary care set-up in India	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2023	4.50	2 Years
A multicenter retrospective study on the prognostic impact of pregnancy in women with history of BRCA mutated breast cancer.	Dr. Jyoti Bajpai	TMH AND Institut Jules Bordet	Non-Government	Medical & Health Sciences	2022	1.32	2 Years
Protocol No. - CA-170-302 : A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3).	Dr. Nandini Menon	Aurigene Discovery Technologies Limited	Non-Government	Medical & Health Sciences	2022	68.24	10 Years

Compilation of data as received from
 Dear Academic of various CI's/OCC of HBNI.

प्र. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलपति / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Evaluation of Saragene HPV -HR test kit and its comparison with Cobas 4800 HPV test kit for detection of High-Risk genotypes of Human Papillomavirus.	Dr. Gaurav Salunke	Cosara Diagnostics Pvt Ltd	Non-Government	Medical & Health Sciences	2022	2.07	6 Months
Early Detection of Common Cancers among Women in India	Dr. Rajendra Badwe	National Institute Of Health, USA	Non-Government	Medical & Health Sciences	1996	40.81	26 Years
Supply of graphite electrode based plasma torch assembly for generating 25kW Plasma arc at 50V and 500A	Dr. Vishal Jain	Gujtex Engineering Company	Non-Government	Engineering Sciences	2022	3.30	8 months
Supply of DBD based plasma system	Mr. Chirayu Patil	Institute of Pharmacy, Nirma University	Non-Government	Engineering Sciences	2022	4.30	3 months
Beyond Standard Model Physics with Neutrino and Dark Matter at Energy, Intensity and Cosmic Frontiers	Dr. Manimala Mitra	Centre Franco-Indian Pour la Promotion De La Recherche A Vancee	Non-Government	Physical Sciences	2020	4.75	3 years
eLife Ben Barres Spotlight Award	Dr. Swagata Ghatak	Ben Barres Spotlight Award	Non-Government	Life Science	2023	1.66	3 years

Compilation of data as received from Dean-Academic of various CI's/oc of HBNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

